Skip to main content
CABA
NASDAQ Life Sciences

Cabaletta Bio's Rese-Cel Shows 80% Pivotal Response in Myositis, Plans SSc Registrational Study

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.83
Mkt Cap
$600.042M
52W Low
$1.26
52W High
$4.23
52W Position info
204% above low
Off High info
9.5% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

CABA has more than doubled off its 52-week low of $1.26.

Summary

Cabaletta Bio announced strong clinical data for its rese-cel therapy across multiple autoimmune indications. The RESET-Myositis trial showed an 80% pivotal response signal in dermatomyositis patients, with 83% achieving IM-free moderate-to-major TIS. Encouraging early preconditioning-free data was also reported for lupus, and a registrational study for systemic sclerosis (SSc) is planned for Q4 2026. This follows recent positive clinical data announcements for rese-cel in other indications and a highly dilutive $141 million financing that extended its cash runway to mid-2027. The 80% pivotal response signal in myositis is highly significant, suggesting a strong path towards regulatory approval for a severe autoimmune disease, which is critical for a company that recently issued a 'going concern' warning. Topline data for the DM/ASyS registrational cohort is expected mid-2027, and the SSc registrational study is planned to start in Q4 2026.

At the time of this announcement, CABA was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $600M. The 52-week trading range was $1.26 to $4.23. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CABA - Latest Insights

CABA
Nov 08, 2026, 10:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $0.9699 info
Change: -$0.3697 (-28%) info
Market Cap: $201.936M info
CABA
Nov 05, 2026, 7:34 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.48
Real-time Price: $0.9699 info
Change: -$0.5101 (-34%) info
Market Cap: $201.936M info
CABA
Nov 05, 2026, 7:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.9699 info
Change: -$0.5101 (-34%) info
Market Cap: $201.936M info
CABA
Sep 14, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $0.9699 info
Change: -$1.80 (-65%) info
Market Cap: $201.936M info
CABA
Aug 13, 2026, 7:34 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $0.9699 info
Change: -$1.85 (-66%) info
Market Cap: $201.936M info